DelMar Pharmaceuticals to Present Two Abstracts at American Association of Cancer Research (AACR) Annual Meeting

New data demonstrates VAL-083 has promise as a potential treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM)

News provided by

DelMar Pharmaceuticals, Inc.

Apr 02, 2014, 01:20 ET

VANCOUVER, British Columbia and MENLO PARK, Calif., April 2, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company would present two abstracts at the 105th Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 5-9, 2014, in San Diego.

The Company will present abstract number 824, entitled "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer," during the Novel Cytotoxic Strategies Session on Sunday, April 6, 2014, 1:00 pm to 5:00 pm. A link to the Company's abstract can be found here: DMPI NSCLC AACR2014.

DelMar will also present an update on its ongoing clinical trial of VAL-083 in the treatment of refractory glioblastoma. The abstract number CT404, entitled "Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme," will be presented during the Early Phase Clinical Trials 2 session on Wednesday, April 9, 2014, 8:00 am to 12:00 pm. A link to the abstract can be found here: DMPI GBM AACR2014.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 has been extensively studied by U.S. National Cancer Institute and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action which distinct from current therapies.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, [email protected].

Follow DelMar on Twitter @DelMarPharma or Facebook.com/DelMarPharma.

SOURCE DelMar Pharmaceuticals, Inc.